AR101101A1 - Composición farmacéutica que comprende un agente terapéutico basado en proteína hemoglobina recombinante o subunidad para el tratamiento dirigido hacia el cáncer - Google Patents

Composición farmacéutica que comprende un agente terapéutico basado en proteína hemoglobina recombinante o subunidad para el tratamiento dirigido hacia el cáncer

Info

Publication number
AR101101A1
AR101101A1 ARP150102131A ARP150102131A AR101101A1 AR 101101 A1 AR101101 A1 AR 101101A1 AR P150102131 A ARP150102131 A AR P150102131A AR P150102131 A ARP150102131 A AR P150102131A AR 101101 A1 AR101101 A1 AR 101101A1
Authority
AR
Argentina
Prior art keywords
cancer
recombinant hemoglobin
protein
subunit
tetramer
Prior art date
Application number
ARP150102131A
Other languages
English (en)
Original Assignee
Cheer Global Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cheer Global Ltd filed Critical Cheer Global Ltd
Publication of AR101101A1 publication Critical patent/AR101101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

El agente terapéutico basado en proteína o tetrámero o dímero o subunidad de hemoglobina recombinante es también eficaz para tratar el cáncer. El resto de hemoglobina recombinante o tetrámero o dímero o su subunidad puede ser dirigido hacia células cancerígenas y el resto terapéutico (es decir, agente activo / fármaco terapéutico) puede matar a las células cancerígenas en forma eficaz. El agente terapéutico basado en proteína recombinante o tetrámero o dímero o su subunidad empleado puede utilizarse en el tratamiento de diversos cánceres tales como cáncer pancreático, leucemia, cáncer de cabeza y cuello, cáncer colorrectal, cáncer pulmonar, cáncer mamario, cáncer hepático, cáncer nasofaríngeo, cáncer esofágico, cáncer de próstata, cáncer de estómago y cáncer cerebral. La composición puede utilizarse por si sola o en combinación con otro(s) agente(s) terapéutico(s) tales como un agente quimioterapéutico, un agente radioterapéutico, un fármaco proteico anticancerígeno para proporcionar un efecto sinérgico en el tratamiento del cáncer, inhibiendo la metástasis y/o reduciendo la recurrencia. Reivindicación 1: Una proteína hemoglobina recombinante, con o sin hemo, que comprende tetrámero, dímero, y/o subunidad de hemoglobina recombinante como un portador y suministro de oxígeno reemplazando a la molécula de hemoglobina natural o nativa aislada y/o purificada de una fuente animal o humana. Reivindicación 2. La proteína hemoglobina recombinante de la reivindicación 1, donde dicha subunidad de hemoglobina recombinante es un monómero de hemoglobina recombinante que es construido y expresado en base a una secuencia de 141 - 146 aminoácidos originados de Homo sapiens. Reivindicación 9: Un método para preparar la molécula de hemoglobina recombinante de la reivindicación 1 el cual comprende construir un gen de fusión que codifica para la proteína, tetrámero, dímero y/o subunidad de hemoglobina recombinante, insertar el gen de fusión en un vector, insertar el vector en un organismo huésped y expresar dicha proteína, tetrámero, dímero o subunidad de la reivindicación 1.
ARP150102131A 2014-07-02 2015-07-02 Composición farmacéutica que comprende un agente terapéutico basado en proteína hemoglobina recombinante o subunidad para el tratamiento dirigido hacia el cáncer AR101101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462019925P 2014-07-02 2014-07-02

Publications (1)

Publication Number Publication Date
AR101101A1 true AR101101A1 (es) 2016-11-23

Family

ID=55016241

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102131A AR101101A1 (es) 2014-07-02 2015-07-02 Composición farmacéutica que comprende un agente terapéutico basado en proteína hemoglobina recombinante o subunidad para el tratamiento dirigido hacia el cáncer

Country Status (12)

Country Link
US (1) US9814759B2 (es)
EP (1) EP3164412A4 (es)
KR (1) KR20170026485A (es)
CN (1) CN106715468A (es)
AR (1) AR101101A1 (es)
AU (1) AU2015283394B2 (es)
CA (1) CA2953173A1 (es)
HK (1) HK1232242A1 (es)
SG (2) SG11201610947UA (es)
TW (1) TWI633118B (es)
UY (1) UY36202A (es)
WO (1) WO2016000616A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202014011600U1 (de) 2013-10-18 2023-05-31 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Markierte Inhibitoren des prostataspezifischen Membranantigens (PSMA), deren Verwendung als bildgebende Mittel und pharmazeutische Wirkstoffe für die Behandlung von Prostatakrebs
US11560384B2 (en) 2017-05-04 2023-01-24 University Of Utah Research Foundation Benzonorbornadiene derivatives and reactions thereof
US10946099B2 (en) * 2017-06-27 2021-03-16 Vision Global Holdings Limited Compositions for photodynamic therapy and fluorescence diagnosis of cancers and other diseases
CN110256571A (zh) * 2018-11-30 2019-09-20 莱尔芙高新技术(上海)有限公司 重组人白蛋白-血红蛋白β亚基融合蛋白
US10752672B1 (en) 2019-02-01 2020-08-25 Cheer Global Limited Recombinant hemoglobins and methods of preparation and use thereof
JPWO2020241340A1 (es) * 2019-05-24 2020-12-03
CA3144719A1 (en) * 2019-07-19 2021-01-28 Cheer Global Limited Hemoglobin-based therapeutic agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600531A (en) 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US5449759A (en) 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US5599907A (en) 1989-05-10 1997-02-04 Somatogen, Inc. Production and use of multimeric hemoglobins
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US6172039B1 (en) * 1990-04-16 2001-01-09 Apex Bioscience, Inc. Expression of recombinant hemoglobin and hemoglobin variants in yeast
CA2122717C (en) * 1991-11-08 2003-07-15 David C. Anderson Hemoglobins as drug delivery agents
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
WO2006113540A2 (en) * 2005-04-14 2006-10-26 Duke University Use of ntrosylated hemoglobin
US7989593B1 (en) 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US8742073B2 (en) 2010-05-27 2014-06-03 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US7932356B1 (en) 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
US8048856B1 (en) 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US8084581B1 (en) 2011-04-29 2011-12-27 Bing Lou Wong Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
US20130052232A1 (en) 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US9636404B2 (en) * 2013-05-13 2017-05-02 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging

Also Published As

Publication number Publication date
AU2015283394A1 (en) 2017-01-19
WO2016000616A1 (en) 2016-01-07
US9814759B2 (en) 2017-11-14
UY36202A (es) 2016-01-29
EP3164412A1 (en) 2017-05-10
TWI633118B (zh) 2018-08-21
SG11201610947UA (en) 2017-01-27
CN106715468A (zh) 2017-05-24
TW201613960A (en) 2016-04-16
CA2953173A1 (en) 2016-01-07
EP3164412A4 (en) 2018-03-28
AU2015283394B2 (en) 2019-04-11
KR20170026485A (ko) 2017-03-08
SG10201807554QA (en) 2018-10-30
US20160000864A1 (en) 2016-01-07
HK1232242A1 (zh) 2018-01-05

Similar Documents

Publication Publication Date Title
AR101101A1 (es) Composición farmacéutica que comprende un agente terapéutico basado en proteína hemoglobina recombinante o subunidad para el tratamiento dirigido hacia el cáncer
CO2018004564A2 (es) Genes de ataxia de friedreich modificados y vectores para terapia génica
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
UY36969A (es) Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon
CO2018005215A2 (es) Construcciones específicas del hígado para expresión del factor viii
BR112017018383A2 (pt) inclusão de éxon2 induzida por anti-sentido em alfa-glucosidase ácida
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
EA201891092A1 (ru) Способы и композиции для редактирования генов в гемопоэтических стволовых клетках
TR201820102T4 (tr) Fabri hastalığı gen tedavisi.
SA515370134B1 (ar) تركيبة صيدلانية تحتوي على عامل علاجي قائم على الهيموغلوبين المعدل لعلاج السرطان المستهدف والتصوير التشخيصي
BR112018015659A2 (pt) genes otimizados do fator viii
MX2017011847A (es) Modulación de inmunidad tumoral por liberación de o2 mediada por proteína.
EP4378962A3 (en) Anti-cancer fusion polypeptide
WO2014179331A3 (en) Devices, systems and methods for optogenetic modulation of action potentials in target cells
MX2016003943A (es) Composiciones y formulaciones para la prevencion y reduccion de tumorigenesis, invasion y proliferacion de celulas de cancer y metodos de produccion y uso en el tratamiento del cancer.
MX2018002524A (es) Composicion farmaceutica que contiene, como ingrediente activo, proteina de fusion en la que el peptido de tumor-penetrante y el agente anti-angiogenesis se funden, para prevenir y tratar el cancer o enfermedades relacionadas a la angiogenesis.
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
MX2018005886A (es) Composiciones y metodos para la expresion de polipeptidos biologicamente activos a partir de un vector unico para tratamiento de condiciones cardiacas y otras patologias.
NZ721607A (en) Fusion protein inhibiting angiogenesis or growth and use thereof
PE20191786A1 (es) Anticuerpo monoclonal para pd-l1
BR112014026162A2 (pt) Proteína de fusão ou variante da mesma, molécula de ácido nucleico, vetor de expressão, célula hospedeira, animal não humano geneticamente modificado, planta geneticamente modificada, agente terapêutico para doenças melhoradas por lactoferrina, composição farmacêutica, e, método para preparar a proteína de fusão ou variante da mesma
PH12015501995A1 (en) Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment
BR112016028641A2 (pt) ?método para tratar câncer?
IN2014DN06920A (es)
MX2018015172A (es) Metodos para tratar cancer pancreatico.

Legal Events

Date Code Title Description
FB Suspension of granting procedure